Janux Therapeutics, Inc.

NASDAQ:JANX

Biotechnology

Healthcare
$10.31 -1.74%

-$0.25 today

Market cap
$630.80M
Beta
2.52
P/E (TTM)
-7.6
EPS (TTM)
-$1.83
52W Low $12.12High $35.34

Volume 0.98M

Average 1.02M

JANX Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Janux Therapeutics, Inc.NASDAQ: JANX

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit turns positive

Q1 FY2026 gross profit was $3.26M, compared with -$25.06M a year earlier. Trailing-twelve-month gross profit was $11.7M. Over 3 fiscal years it compounded at +0.9% a year.

Context

  • Gross profit amounted to 79.7% of revenue in FY2025, down 0.8 pp from a year earlier.
  • Gross profit increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly gross profit holds near $3.26M or moves back toward the trailing-twelve-month quarterly average of $2.93M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.26M+407.9% QoQ
Last fiscal yearDec 2025
$7.97M-6.5% YoY
LTMMar 2026
$11.7M+129.7% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+113.0%——
1 year-6.5%——
3-year CAGR+0.9%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
7.97M USD
Year-over-year change
-6.5%

Gross Profit vs competitors

How JANX compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +129.7% is the highest of 10, against a peer median of +16.2%.
  • Gross profit amounts to 54.1% of revenue for JANX, versus a peer median of 99.0%.
JANX Competitors
Gross Profit for JANX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$774.12M USD+40.6%+129.1%57.0%
MGNXMacroGenics, Inc.LTM Mar 2026$109.85M USD+16.2%-9.3%69.9%
STROSutro Biopharma, Inc.LTM Mar 2026$98.33M USD+52.1%+17.0%98.7%
IMTXImmatics N.V.LTM Mar 2026€37.3M EUR-74.1%-9.9%100.0%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$35.29M USD-76.1%+12.8%99.3%
JANXJanux Therapeutics, Inc.LTM Mar 2026$11.7M USD+129.7%+0.9%54.1%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026-$79K USD-2.6%——
CMPXCompass Therapeutics, Inc.LTM Mar 2026-$738K USD-186.8%——
CLDXCelldex Therapeutics, Inc.LTM Sep 2026-$742K USD+99.6%—662.5%
IMNMImmunome, Inc.LTM Sep 2026-$753K USD+98.1%——
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding JANX) —+16.2%+12.8%99.0%

Competitors are the stored peer set for JANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.64M8.61M8.08M10.59M10M
Cost of Revenue26.24M841K1.96M2.06M2.03M
Gross Profit(22.6M)7.77M6.13M8.53M7.97M
Gross Margin-621.4%90.2%75.8%80.5%79.7%
Research & Development26.24M53.44M54.92M68.39M125.9M
Selling, General & Admin10.33M22.26M26.14M41.05M41.77M
Operating Expenses10.33M74.86M79.11M107.38M165.64M
Depreciation & Amortization113K841K1.96M2.06M2.03M
EBITDA(32.56M)(62.22M)(56.34M)(66.93M)(111.6M)
EBITDA Margin-895.2%-722.5%-697.0%-632.2%-1116.0%
Operating Income(32.93M)(67.09M)(72.98M)(98.85M)(157.67M)
Operating Margin-905.4%-779.0%-902.9%-933.6%-1576.7%
Interest Income257K4.03M14.69M29.85M44.04M
Interest Expense00000
Other Income / Expenses257K4.03M14.69M29.85M44.04M
Income Before Tax(32.67M)(63.06M)(58.29M)(68.99M)(113.63M)
Pre-Tax Margin-898.3%-732.2%-721.2%-651.6%-1136.3%
Income Tax Expense00000
Net Income(32.67M)(63.06M)(58.29M)(68.99M)(113.63M)
Net Margin-898.3%-732.2%-721.2%-651.6%-1136.3%
EPS (Basic)(0.79)(1.52)(1.32)(1.28)(1.83)
EPS (Diluted)(0.79)(1.52)(1.32)(1.28)(1.83)
Weighted Avg Shares41.24M41.47M44.02M53.75M61.97M
Weighted Avg Shares (Diluted)41.24M41.47M44.02M53.75M61.97M

Janux Therapeutics, Inc.

NASDAQ:JANX

Intrinsic Alpha fair value

Locked

Current Price

$10.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.